ES476496A1 - Procedimiento para preparar derivados de acido ftalazin-4- ilacetico. - Google Patents
Procedimiento para preparar derivados de acido ftalazin-4- ilacetico.Info
- Publication number
- ES476496A1 ES476496A1 ES476496A ES476496A ES476496A1 ES 476496 A1 ES476496 A1 ES 476496A1 ES 476496 A ES476496 A ES 476496A ES 476496 A ES476496 A ES 476496A ES 476496 A1 ES476496 A1 ES 476496A1
- Authority
- ES
- Spain
- Prior art keywords
- formula
- radical
- compound
- hydrogen
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Procedimiento para preparar derivados de ácido ftalazin-4-ilacético , de fórmula:**fórmula**, donde R1 es un radical hidroxi o benciloxi, o un radical acolxi C1-4 portando opcionalmente un radical N-morfolino o dialquilamino C1-4; y los sustituyentes R2, R3, R4 y R5 en el anillo de benceno A son seleccionados a partir de cualquiera de las siguientes combinaciones: a) R2 es un radical fluor o metoxi , R3 es hidrógeno, R4 es un radical cloro, bromo o yodo, y R5 es hidrógeno o un radical halógeno; b) R2,R3 y R5 son hidrógeno, y R4 es un radical bromo o yodo c) R2 es hidrógeno o un radical flúor, R3 y R5 son iguales o distintos radicales halógeno, y R4 es hidrógeno; d) R2 es hidrógeno o un radical fluor, R3 y R4 son iguales o distintos radicales halógeno, y R5 es hidrógeno; y e) R2 es hidrógeno, R3 y R5 son, independientemente, radicales flúor o cloro, y R4 es un radical cloro, bromo o yodo; y donde e, en el anillo de benceno B, R6,R7 y R8 son seleccionados independientemente entre hidrógeno, halógeno y radicales alquilo C1-4 y alcoxi C1-4, o bien R6 y R7 juntos constituyen un radical bivalente alquilenoxidioxi; a condición de que por lo menos uno de R6,R7 y R8 sea hidrógeno; y X es oxígeno o azufre, o una sal básica de adición farmaceúticamente aceptable de un compuesto de la fórmula I dónde R1 es un radical hidroxi, o una sal ácida de adición farmaceuticamente aceptable de un compuesto de la fórmula I donde R1 es un radical alcoxi C1-4, portando un radical N-morfolino o dialquilamino C1-4; caracterizado porque comprende: a) para un compuesto de fórmula I donde X es oxígeno, reaccionar un compuesto de fórmula: **fórmula** con haluro de fórmula **fórmula** donde Hal es un radical cloro, bromo o yodo, en presencia de una base apropiada; b) para un compuesto de la fórmula I donde R1 es un radical hidroxi, hidrolizar un éster de fórmula: **fórmula** donde R9 es un radical alcoxi C1-4 ó un radical de fórmula: **fórmula** c) para un compuesto de la fórmula I donde X es oxígeno, reaccionar un compuesto de fórmula: **fórmula** o un isómero geométrico del mismo, con una hidrazina de fórmula ** fórmula** d) para un compuesto de la fórmula I donde X es oxígeno y R1 es un radical hidroxi o un radical alcoxi C1-4, descomponer por catálisis una diazocetona de fórmula: fórmula en presencia de un compuesto de la fórmula Q.H, donde Q es un radical hidroxi o alcoxi C1-4; e) para un compuesto de la fórmula I donde R1 es un radical hidroxi, descarboxilar un ácido malónico de la siguiente fórmula: **fórmula** f) para un compuesto de la fórmula I donde el anillo de benceno B porta un radical alcoxi C1-4, reaccionar un compuesto de la fórmula I donde el anillo benceno B porta un radical halógeno con un alcóxido C1-4 metálico alcalino; y luego , cuando se requiere un compuesto de la fórmula I donde R1 no es un radical hidroxi, un compuesto de la fórmula I donde R1 es un radical hidroxi o un derivado reactivo del mismo, se hace reaccionar con un compuesto de la fórmula R10.H, donde R10 tiene el mismo significado que R1 que no sea una radical hidroxi, usando procedimientos de esterificación conocidos, y cuando se requiere un compuesto de la fórmula I donde X es azufre, un compuesto de la fórmula I donde X es oxígeno, se sulfura por los procedimientos de sulfuración conocidos, y cuando se requiere una sal farmacéuticamente aceptable, se hace reaccionar un compuesto de la fórmula I, donde R1 es un radical hidroxi, con una base que ofrezca un catión farmacéuticamente aceptable, o se hace reaccionar un compuesto de la fórmula I, donde R1 es un radical alcoxi C1-4 portando un radical N-mormolino o di-N,N-alquilamino C1-4 con un ácido que ofrezca un anión farmacéuticamente aceptable, y donde X , los anillos de benceno A y B, y los sustituyentes en los mismos, tienen cualquiera de los significados definidos anteriormente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB5414277 | 1977-12-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES476496A1 true ES476496A1 (es) | 1979-04-16 |
Family
ID=10470067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES476496A Expired ES476496A1 (es) | 1977-12-29 | 1978-12-29 | Procedimiento para preparar derivados de acido ftalazin-4- ilacetico. |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US4251528A (es) |
| EP (1) | EP0002895B1 (es) |
| JP (2) | JPS5495582A (es) |
| AT (1) | AT365581B (es) |
| AU (1) | AU516264B2 (es) |
| BG (1) | BG34336A3 (es) |
| CA (1) | CA1107732A (es) |
| CS (1) | CS241015B2 (es) |
| CY (1) | CY1219A (es) |
| DD (1) | DD141021A5 (es) |
| DE (1) | DE2861170D1 (es) |
| DK (1) | DK151253C (es) |
| ES (1) | ES476496A1 (es) |
| FI (1) | FI64357C (es) |
| GR (1) | GR65303B (es) |
| HK (1) | HK22484A (es) |
| HU (1) | HU182585B (es) |
| IE (1) | IE47592B1 (es) |
| IL (1) | IL56099A0 (es) |
| IN (1) | IN150196B (es) |
| IT (1) | IT1110885B (es) |
| MY (1) | MY8500359A (es) |
| NO (1) | NO154346C (es) |
| NZ (1) | NZ189034A (es) |
| PH (1) | PH15435A (es) |
| PL (1) | PL118443B1 (es) |
| PT (1) | PT68956A (es) |
| SG (1) | SG68683G (es) |
| SU (3) | SU1087075A3 (es) |
| YU (3) | YU41607B (es) |
| ZW (1) | ZW24978A1 (es) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE47592B1 (en) * | 1977-12-29 | 1984-05-02 | Ici Ltd | Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture |
| CA1143733A (en) * | 1979-07-31 | 1983-03-29 | Masao Yoshida | Producing 7-alkoxycarbonyl-6,8-dimethyl-4- hydroxymethyl-1-phthalazone and intermediates |
| US4762839A (en) * | 1985-06-06 | 1988-08-09 | Tanabe Seiyaku Co., Ltd. | Quinazolinone copmpounds useful for the prophyloxis and treatment of diabetic complications |
| ES2032749T3 (es) * | 1985-11-07 | 1993-03-01 | Pfizer Inc. | Acidos oxoftalazinil-aceticos heterociclicos. |
| JPS63132889A (ja) * | 1986-11-21 | 1988-06-04 | Tanabe Seiyaku Co Ltd | キナゾリノン誘導体 |
| US5011840A (en) * | 1986-11-24 | 1991-04-30 | Pfizer Inc. | Imidazolidinedione derivatives in diabetes treatment |
| GB8704569D0 (en) * | 1987-02-26 | 1987-04-01 | Ici America Inc | Therapeutic agent |
| US4868301A (en) * | 1987-06-09 | 1989-09-19 | Pfizer Inc. | Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains |
| JPH0676391B2 (ja) * | 1987-06-09 | 1994-09-28 | フアイザー・インコーポレイテツド | ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法 |
| IL88150A0 (en) * | 1987-11-02 | 1989-06-30 | Merck & Co Inc | Pharmaceutical tablet compositions containing phthalizine acetic acid compounds |
| DK607188A (da) * | 1987-11-02 | 1989-06-22 | Merck & Co Inc | Tablet indeholdende en phthalazineddikesyreforbindelse |
| US4880928A (en) * | 1987-12-21 | 1989-11-14 | Merck & Co., Inc. | Process for the preparation of 3-((4-bromo-2-fluorophenyl)methyl)-3,4-dihydro-4-oxo-1-phthalazine-acetic acid |
| US4940791A (en) * | 1988-02-29 | 1990-07-10 | Pfizer Inc. | Process for the production of phthalazineacetic acid ester derivatives and a novel hydrazine containing intermediate |
| US4904782A (en) * | 1988-02-29 | 1990-02-27 | Pfizer Inc. | Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate |
| US4954629A (en) * | 1989-05-11 | 1990-09-04 | Pfizer Inc. | Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof |
| US4996204A (en) * | 1989-05-11 | 1991-02-26 | Pfizer Inc. | Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors |
| EP0397930A1 (en) * | 1989-05-18 | 1990-11-22 | Merck & Co. Inc. | Process for the preparation of 3-[(4-bromo-2-fluorophenyl) methyl]-3,4-dihydro-4-oxo-1-phthalazineacetic acid |
| FR2647676A1 (fr) * | 1989-06-05 | 1990-12-07 | Union Pharma Scient Appl | Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase |
| US5304557A (en) * | 1989-12-15 | 1994-04-19 | Pfizer Inc. | Substituted oxoophthalazinyl acetic acids and analogs thereof |
| US5037831A (en) * | 1990-05-21 | 1991-08-06 | American Home Products Corporation | Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors |
| FR2682108B1 (fr) * | 1991-10-07 | 1994-01-07 | Lipha | Acide 3,4-dihydro-4-oxo-3(prop-2-enyl)-1-phtalazineacetiques et derives, leurs preparations et medicaments les contenant. |
| NZ254550A (en) * | 1992-09-28 | 1997-08-22 | Pfizer | Use of nitrogen-substituted pyrimidines to prepare medicaments useful for treatment or prevention of diabetic complications |
| JPH08502973A (ja) * | 1992-11-02 | 1996-04-02 | メルク エンド カンパニー インコーポレーテッド | ニューロテンシンアンタゴニストとしての置換フタラジノン |
| CH683965A5 (it) * | 1993-02-19 | 1994-06-30 | Limad Marketing Exp & Imp | Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici. |
| JPH09506068A (ja) * | 1993-07-26 | 1997-06-17 | 藤沢薬品工業株式会社 | 悪液質治療のためのオキソフタラジン類 |
| US6696407B1 (en) | 1997-03-21 | 2004-02-24 | The Regents Of The University Of California | Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF |
| AU6473898A (en) * | 1997-03-21 | 1998-10-20 | Regents Of The University Of California, The | Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors |
| ATE422359T1 (de) * | 1997-04-15 | 2009-02-15 | Csir | Verbindungen und pharmazeutische zusammensetzungen mit appetitunterdrückender aktivität |
| SK7522001A3 (en) * | 1998-03-31 | 2002-02-05 | Inst For Pharm Discovery Inc | Substituted indolealkanoic acids |
| TNSN99224A1 (fr) | 1998-12-01 | 2005-11-10 | Inst For Pharm Discovery Inc | Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique |
| GB2396815B (en) * | 1999-10-27 | 2004-09-08 | Phytopharm Plc | A composition comprising a pregnenone derivative and an NSAID |
| DE19963607B4 (de) * | 1999-12-23 | 2005-12-15 | Schering Ag | Verfahren zur Herstellung von 4-(Heteroaryl-methyl) halogen-1(2H)-phthalazinonen |
| GB2363985B (en) | 2000-06-30 | 2004-09-29 | Phytopharm Plc | Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use |
| HRP20030419A2 (en) * | 2000-11-30 | 2004-08-31 | Pfizer Prod Inc | Combination of gaba agonists and aldose reductase inhibitors |
| ES2240657T3 (es) | 2001-02-28 | 2005-10-16 | Pfizer Products Inc. | Compuestos de sulfonilpiridazinona utiles como inhibidores de aldosa reductasa. |
| ATE348100T1 (de) * | 2001-03-30 | 2007-01-15 | Pfizer Prod Inc | Zwischenprodukten für die herstellung von pyridazinon aldose reductase inhibitoren. |
| AU2002236131B2 (en) * | 2001-04-30 | 2005-04-14 | Pfizer Products Inc. | Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors |
| AU761191B2 (en) | 2001-05-24 | 2003-05-29 | Pfizer Products Inc. | Therapies for tissue damage resulting from ischemia |
| WO2003092696A1 (en) * | 2002-04-30 | 2003-11-13 | Novartis Ag | Method for decreasing capillary permeability in the retina |
| KR20050026002A (ko) * | 2002-07-26 | 2005-03-14 | 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 | 치환된 인돌알칸산 유도체 및 이를 함유하는 당뇨 합병증치료용 제형 |
| US7572910B2 (en) * | 2003-02-20 | 2009-08-11 | Pfizer, Inc. | Pyridazinone aldose reductase inhibitors |
| US20110092566A1 (en) * | 2004-11-19 | 2011-04-21 | Srivastava Satish K | Treatment of cancer with aldose reductase inhibitors |
| JP4838582B2 (ja) * | 2004-12-27 | 2011-12-14 | 岐阜プラスチック工業株式会社 | 台車用本体 |
| ATE518544T1 (de) | 2007-03-12 | 2011-08-15 | Zadec Aps | Rotbusch-extrakt gegen diabetes |
| CA2685202C (en) | 2007-03-23 | 2017-11-28 | The Board Of Regents Of The University Of Texas System | Methods for treating allergic asthma |
| US20090270490A1 (en) * | 2008-04-24 | 2009-10-29 | The Board Of Regents Of The University Of Texas System | Methods involving aldose reductase inhibition |
| CA2822672C (en) | 2010-12-23 | 2018-06-05 | The Board Of Regents Of The University Of Texas System | Methods for treating copd |
| WO2014093988A2 (en) * | 2012-12-14 | 2014-06-19 | Phusis Therapeutics, Inc. | Methods and compositions for inhibiting cnksr1 |
| US10227356B2 (en) | 2015-04-20 | 2019-03-12 | Phusis Therapeutics, Inc. | Compounds, compositions and methods for inhibiting CNKSR1 |
| US12090142B2 (en) | 2018-02-22 | 2024-09-17 | Board Of Regents, The University Of Texas System | Combination therapy for the treatment of cancer |
| JP6936290B2 (ja) * | 2018-10-04 | 2021-09-15 | 日東電工株式会社 | 耐熱離型シート及び熱圧着方法 |
| JP6751974B1 (ja) * | 2019-10-16 | 2020-09-09 | 株式会社コバヤシ | 離型フィルム及び離型フィルムの製造方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3833579A (en) * | 1935-11-11 | 1974-09-03 | Inoue Michiro | 4-carbamoyl phthalazones |
| JPS5116430B2 (es) * | 1971-08-05 | 1976-05-24 | ||
| GB1398549A (en) * | 1972-11-06 | 1975-06-25 | Boots Co Ltd | Phthalazine derivatives and their use in pharmaceutical compo sitions |
| AR205004A1 (es) * | 1973-10-30 | 1976-03-31 | Ishikawa M | Procedimiento para preparar derivados de 6,8-dialquil-7-alcoxi-carbonil-4-hidroximetil-1-ftalazona y la 7,8-lactona |
| DE2451117A1 (de) * | 1973-10-31 | 1975-05-22 | Boots Co Ltd | Therapeutisch wirksame verbindungen |
| GB1502312A (en) | 1975-03-20 | 1978-03-01 | Ici Ltd | Quinolone derivatives |
| IE43079B1 (en) * | 1975-03-20 | 1980-12-17 | Ici Ltd | Quinolone derivatives |
| JPS5214788A (en) * | 1975-07-21 | 1977-02-03 | Fuji Photo Film Co Ltd | Process for preparing phthalazinone and its derivatives |
| NL7702763A (nl) * | 1976-03-18 | 1977-09-20 | Takio Shimamoto En Masayuki Is | Werkwijze voor de bereiding van thromboxaan- -antagonisten en van preparaten die deze stof- fen bevatten. |
| IE47592B1 (en) * | 1977-12-29 | 1984-05-02 | Ici Ltd | Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture |
| US4293553A (en) * | 1978-08-11 | 1981-10-06 | Masayuki Ishikawa | 1-Phthalazone derivatives, and use thereof |
-
1978
- 1978-11-27 IE IE2337/78A patent/IE47592B1/en not_active IP Right Cessation
- 1978-11-28 NZ NZ189034A patent/NZ189034A/xx unknown
- 1978-11-28 IN IN860/DEL/78A patent/IN150196B/en unknown
- 1978-11-29 US US05/964,725 patent/US4251528A/en not_active Expired - Lifetime
- 1978-11-29 AU AU42040/78A patent/AU516264B2/en not_active Expired
- 1978-11-30 IL IL56099A patent/IL56099A0/xx not_active IP Right Cessation
- 1978-11-30 DK DK541878A patent/DK151253C/da not_active IP Right Cessation
- 1978-12-01 DE DE7878300720T patent/DE2861170D1/de not_active Expired
- 1978-12-01 EP EP78300720A patent/EP0002895B1/en not_active Expired
- 1978-12-01 CY CY1219A patent/CY1219A/xx unknown
- 1978-12-06 PH PH21901A patent/PH15435A/en unknown
- 1978-12-12 GR GR57849A patent/GR65303B/el unknown
- 1978-12-14 FI FI783844A patent/FI64357C/fi not_active IP Right Cessation
- 1978-12-16 PL PL1978222157A patent/PL118443B1/pl unknown
- 1978-12-20 PT PT68956A patent/PT68956A/pt not_active IP Right Cessation
- 1978-12-20 SU SU782698853A patent/SU1087075A3/ru active
- 1978-12-21 CA CA318,345A patent/CA1107732A/en not_active Expired
- 1978-12-21 JP JP15695378A patent/JPS5495582A/ja active Granted
- 1978-12-22 HU HU78IE856A patent/HU182585B/hu not_active IP Right Cessation
- 1978-12-26 BG BG041857A patent/BG34336A3/xx unknown
- 1978-12-28 NO NO784397A patent/NO154346C/no unknown
- 1978-12-28 IT IT52480/78A patent/IT1110885B/it active
- 1978-12-28 ZW ZW249/78A patent/ZW24978A1/xx unknown
- 1978-12-28 CS CS789084A patent/CS241015B2/cs unknown
- 1978-12-29 YU YU3127/78A patent/YU41607B/xx unknown
- 1978-12-29 DD DD78210284A patent/DD141021A5/de not_active IP Right Cessation
- 1978-12-29 ES ES476496A patent/ES476496A1/es not_active Expired
- 1978-12-29 AT AT0937678A patent/AT365581B/de not_active IP Right Cessation
-
1980
- 1980-10-06 US US06/194,211 patent/US4393062A/en not_active Expired - Lifetime
-
1981
- 1981-12-04 SU SU813359636A patent/SU1072803A3/ru active
- 1981-12-04 SU SU813359216A patent/SU1272984A3/ru active
-
1982
- 1982-10-14 YU YU2321/82A patent/YU42807B/xx unknown
- 1982-10-14 YU YU2320/82A patent/YU42054B/xx unknown
-
1983
- 1983-11-11 SG SG68683A patent/SG68683G/en unknown
-
1984
- 1984-03-15 HK HK224/84A patent/HK22484A/en unknown
-
1985
- 1985-12-30 MY MY359/85A patent/MY8500359A/xx unknown
-
1987
- 1987-10-28 JP JP62270508A patent/JPS63119469A/ja active Granted
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES477695A1 (es) | Un procedimiento para preparar derivados de deshidrociclici-minoacidos. | |
| SE7603931L (sv) | Forfarande for framstellning av nya tetracykliska foreningar | |
| ES8601924A1 (es) | Un procedimiento para la preparacion de nuevas 2-amino-5-hidroxi-4-metilpirimidinas. | |
| ES485274A1 (es) | Un procedimiento para la preparacion de derivados de fenil- piperacina | |
| ES8706606A1 (es) | Un procedimiento para preparar aril-hidroxamatos | |
| GB925429A (en) | Indole derivatives | |
| ES8201116A1 (es) | Procedimiento para preparar derivados de 2-nitro-5-(fenoxi sustituido)-benzoilo | |
| WO1979001114A1 (fr) | Dialkyl 4-methylphosphinobutyrates et leur procede de fabrication | |
| GB1461173A (en) | Preparation of 3- 4-or 5-substituted thiazol-2-oxy- propanediol 1,2-acetonides | |
| OA06585A (fr) | Dérivés triazonyl-alcéniques, leur procédé de production et leur utilisation comme fongicides. | |
| ES2060250T3 (es) | Procedimiento para producir beta-caroteno y compuestos intermedios utiles para el procedimiento. | |
| AU568064B2 (en) | 4-acylamino-1-aza-adamantanes | |
| IE792300L (en) | 2,4, 6-triiodoisophthalamic acid derivatives; x-ray¹contrast agents | |
| ES8301888A1 (es) | "procedimiento para la preparacion de derivados de fenoxi-aminopropanol substituidos" como divisional de la patente de invencion n 502.649 del 1 junio 1981. | |
| FR2474488B1 (es) | ||
| GB1082072A (en) | Phenylsulfinylalkanoic acid derivatives | |
| ES459087A1 (es) | Procedimiento para preparar fenilacetilenos sustituidos. | |
| GB2005267A (en) | Indole derivatives their preparation and pharmaceutical compositions containing them | |
| GB2004543A (en) | A process for preparing phenylalkane carboxylic acids | |
| ES8603412A1 (es) | Procedimiento para la obtencion de acemetacina | |
| FR2383184A1 (fr) | Procede de preparation d'ethers | |
| ES8600188A1 (es) | Procedimiento de preparacion de un derivado 1,1-difenilpropan-1-ol | |
| SE8204791D0 (sv) | Process for preparing alkoxy-vincaminic acid esters and alkoxy-apovincaminic acid esters | |
| ES471193A1 (es) | Procedimiento para la preparacion de derivados pirazolinicos | |
| JPS5265251A (en) | Synthesis of prostaglandin derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD1A | Patent lapsed |
Effective date: 20000301 |